Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a Form 8-K Current Report containing Item 5.07 “Submission of Matters to a Vote of Security Holders,” which lists detailed voting results from the company’s Annual Meeting (election of directors, ratification of auditors, charter amendment, etc.). This is an official announcement of shareholder vote outcomes. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category.
2026-05-22 English
10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K current report filed with the SEC on May 6, 2026, under Item 2.02 “Results of Operations and Financial Condition.” It furnishes a press release announcing the company’s first quarter 2026 financial results. This is precisely an earnings release announcing quarterly results. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-06 English
ARS - TScan Therapeutics, Inc. (0001783328) (Filer)
Annual Report
2026-04-17 English
DEF 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
Proxy Solicitation & Information Statement
2026-04-17 English
8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the SEC. Item 5.02 explicitly details the resignation of the Vice President of Finance and principal accounting officer, and the appointment of a new principal accounting officer. This falls squarely under the category of Board/Management Information (MANG).
2026-04-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.